The development of peptide‐coated nanoparticles for targeting and drug delivery to cancer cells

Ovarian Cancer (OC) is a most lethal female malignancy worldwide, mostly due to the late‐stage diagnosis and high recurrence rate. Survival statistics remain stuck at ~30% for the past four decades highlighting the necessity to improve the early stage detection and therapeutic outcomes. Nanotherapy in OC may provide significant and unique benefits for drug efficacy as well as for reducing the therapeutically limiting adverse effects associated...